Tetrahedral DNA nanostructures, graphene and carbon nanodots-based electrochemiluminescent biosensor for BRCA1 gene mutation detection
In this study, we present a novel electrochemiluminescent DNA biosensor designed for detecting breast cancer type 1 (BRCA1) gene mutations. The biosensor integrates graphene nanosheets (Graph-NS), tetrahedral DNA nanostructures (TDNs), and carbon nanodots (CNDs) to enhance sensitivity and specificit...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Autónoma de Madrid |
| Repositorio: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.uam.es:10486/716485 |
| Acceso en línea: | http://hdl.handle.net/10486/716485 https://dx.doi.org/10.1016/j.talanta.2024.127182 |
| Access Level: | acceso abierto |
| Palabra clave: | DNA Biosensor Electrochemiluminescence Breast Cancer Type 1 Carbon Nanodots Tetrahedral DNA Nanostructures Física Química |
| Sumario: | In this study, we present a novel electrochemiluminescent DNA biosensor designed for detecting breast cancer type 1 (BRCA1) gene mutations. The biosensor integrates graphene nanosheets (Graph-NS), tetrahedral DNA nanostructures (TDNs), and carbon nanodots (CNDs) to enhance sensitivity and specificity. Graph-NS are employed to structure the transducer and serve as a platform for DNA immobilization. TDNs are engineered with a BRCA1 gene-specific capture probe located at the apex (TDN-BRCA1), facilitating efficient biorecognition. Additionally, the basal vertices of TDNs are functionalized with amino groups, enabling their attachment to the CSPE/Graph-NS surface via amino-graphene interaction. This platform effectively identifies single-base mutations in the BRCA1 gene utilizing synthesized CNDs as a coreactant and [Ru(bpy) 2+ 3 ] as the luminophore through the coreactant pathway. The developed biosensor demonstrates exceptional sensitivity and can detect a single mutation in the BRCA1 gene. Furthermore, it has been successfully validated in real samples obtained from breast cancer patients, showcasing a remarkable detection limit of 1.41 aM |
|---|